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RatConsiderable evidence indicates a link between systemic inﬂammation and central 5-HT function. This study
used pharmacological magnetic resonance imaging (phMRI) to study the effects of systemic inﬂammatory
events on central 5-HT function. Changes in blood oxygenation level dependent (BOLD) contrast were detected
in selected brain regions of anaesthetised rats in response to intravenous administration of the 5-HT-releasing
agent, fenﬂuramine (10 mg/kg). Further groups of rats were pre-treated with the bacterial lipopolysaccharide
(LPS; 0.5 mg/kg), to induce systemic inﬂammation, or the selective 5-HT2A receptor antagonist MDL100907
prior to fenﬂuramine. The resultant phMRI data were investigated further through measurements of cortical
5-HT release (microdialysis), and vascular responsivity, as well as a more thorough investigation of the role of
the 5-HT2A receptor in sickness behaviour. Fenﬂuramine evoked a positive BOLD response in the motor cortex
(+15.9 ± 2%) and a negative BOLD response in the dorsal raphe nucleus (−9.9 ± 4.2%) and nucleus
accumbens (−7.7 ± 5.3%). In all regions, BOLD responses to fenﬂuramine were signiﬁcantly attenuated by
pre-treatment with LPS (p b 0.0001), but neurovascular coupling remained intact, and fenﬂuramine-evoked
5-HT release was not affected. However, increased expression of the 5-HT2A receptor mRNA and decreased
5-HT2A-dependent behaviour (wet-dog shakes)was a feature of the LPS treatment andmay underpin the altered
phMRI signal. MDL100907 (0.5 mg/kg), 5-HT2A antagonist, signiﬁcantly reduced the BOLD responses to fenﬂur-
amine in all three regions (p b 0.0001) in a similar manner to LPS. Together these results suggest that systemic
inﬂammation decreases brain 5-HTactivity as assessed byphMRI. However, these effects do not appear to beme-
diated by changes in 5-HT release, but are associated with changes in 5-HT2A-receptor-mediated downstream
signalling pathways.
© 2013 Elsevier Inc. Open access under CC BY license. Introduction
Evidence indicates that abnormalities in brain 5-HT function, re-
sponses to citalopram for example, persist in patients who are clinically
recovered from depression, but at risk of relapse (Bhagwagar et al.,
2002). Understanding biological variation in the 5-HT system caused
by key risk factors is central to the search for effective antidepressant
treatment. Inﬂammation is thought to be an important risk factor in
the aetiology of depression (Hughes et al., 2012). Furthermore, anti-
depressant drugs are known to reverse inﬂammation-induced depres-
sion, suggesting that cytokine production may directly affect the 5-HT
system. For example, therapy with the cytokine interferon-α results in
25% of patients suffering from a depressive episode as an adverse effect
which is subsequently managed therapeutically by 5-HT targeted anti-
depressants (Horikawa et al., 2003). Similarly, potent broad-spectrumg Group, Radiobiology Research
4 1865 857127.
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license. inﬂammogens, such as the bacterial endotoxin lipopolysaccharide
(LPS) and attenuatedMycobacterium bovis, have been shown to induce
depressive-like symptoms, often known as sickness behaviours, in ro-
dents and induce changes in the 5-HT system (O'Connor et al., 2009).
Sickness behaviours are deﬁned behavioural adaptations in response
to an invading pathogen and are observed in both human patients
and in rodents (Hart, 1988). They are now thought to arise from an in-
teraction between the immune system and the 5-HT system (O'Connor
et al., 2009). This interaction between 5-HT and the immune system is
bidirectional in nature — clinically depressed patients with no obvious
systemic infection often present with high levels of circulating cyto-
kines and reduced tryptophan levels (Alesci et al., 2005; Levine et al.,
1999). Reduced tryptophan levels indicate a potential link between
the systemic immune system and the central 5-HT system, however,
the mechanisms by which this link is established remain unclear.
The mechanisms by which inﬂammatory molecules affect 5-HT, its
signalling pathways, and subsequent mood, are currently under de-
bate. Dantzer and colleagues have suggested that proinﬂammatory
stimuli, such LPS or interleukin-1β (IL-1β), increase activity in the
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resulting in lowered tryptophan availability and therefore decreased
5-HT synthesis (O'Connor et al., 2009). However, data currently avail-
able is contradictory. Linthorst and colleagues demonstrated increased
5-HT levels in hippocampal dialysates following systemic administra-
tion of LPS or intraventricular administration of IL-1β (Linthorst et al.,
1995), whilst Wilkinson et al. failed to demonstrate any functional link
between systemic infection and central 5-HT levels (Wilkinson et al.,
1991). Decreased presynaptic 5-HT function as amechanism for sickness
behaviours would be consistent with other ﬁndings, including evidence
that LPS and other proinﬂammatory stimuli increase expression of the
5-HT transporter (Ramamoorthy et al., 1995; Zhu et al., 2010), which
would reduce 5-HT availability in the synapse (Jennings et al., 2006).
In vivo functionalmagnetic resonance imaging (fMRI) in combination
with 5-HT-targeted pharmacological challenges, termedpharmacological
MRI (phMRI), offers a translational non-invasive neuroimaging approach
tomodel 5-HT function that is complementary tomeasurements of 5-HT
receptor levels offered by techniques such as positron emission tomogra-
phy (Moresco et al., 2006). phMRI utilises a haemodynamic correlate of
neural activity (the blood oxygenation level dependent [BOLD] signal),
which is considered an aggregate index of excitation–inhibition activity
resulting from afferent neuromodulatory input to a given brain struc-
ture (Logothetis, 2008). Ourselves, and others, have previously demon-
strated in preclinical models that it is possible to monitor 5-HT function
using phMRI, with BOLD signals being sensitive to drug-evoked
increases in endogenous 5-HT levels and 5-HT receptor-speciﬁc modu-
lations of neuronal function (Rauch et al., 2008; Preece et al., 2009).
Moreover, clinical studies have demonstrated that 5-HT augmentation
through 5-HT reuptake blockade (Anderson et al., 2008; Murphy et al.,
2009) evokes region-speciﬁc alterations in BOLD responses both
under baseline conditions and during emotional processing tasks. Al-
though the 5-HT receptor subtypes underpinning 5-HT drug-evoked in-
creases in BOLD are not yet known, our previous studies demonstrated
that fenﬂuramine-evoked changes in activity-dependent gene expres-
sion involved 5-HT2A receptor activation (Hirani et al., 2003).
Taken together, the above studies reinforce the concept that it is
possible to measure the functional effects of 5-HT modulation using
phMRI. The primary aim of this study, therefore, was to use phMRI,
in combination with microdialysis, behavioural, and molecular biolo-
gy approaches, to determine the effects of systemic inﬂammation on
central 5-HT function.
Materials & methods
Animal preparation
Male Sprague–Dawley rats (n = 5 per group, 250–300 g; Harlan,
UK) were anesthetised with 2–3% halothane in a 60:40 mixture of
N2O:O2. Subsequently, halothane was reduced to 1.5–2.0% and the
animalswere tracheotomised and artiﬁcially ventilated. Core body tem-
perature was regulated and maintained at 37 °C throughout the exper-
iment, using both heating and cooling systems within the magnet. The
left femoral artery and vein were cannulated for measurement of
blood pressure, withdrawal of blood samples and to enable i.v. adminis-
tration of drugs or vehicle (0.9% saline). All drug doses were calculated
to maintain injection volumes of 0.1 ml, irrespective of administration
route. Throughout data collection, 0.8–1.0% halothane was used as
maintenance anaesthesia. All experiments were approved by the UK
Home Ofﬁce Animals (Scientiﬁc Procedures) Act (1986) in line with
EU directives on animal experimentation. All experiments were further
approved by local ethical committees in line with the 3Rs principles.
Magnetic resonance imaging
Preliminary dose–response studies using this methodology showed
signiﬁcant activation after administration of fenﬂuramine in the motorcortex, nucleus accumbens and dorsal raphe (data not shown), there-
fore these regions have been focussed on in this study. Animals (n =
5–6/group as speciﬁed in the text)were placed in a quadrature birdcage
radiofrequency coil (internal diameter 5 cm) with an integral stereo-
taxic frame. Electrocardiogram (ECG) was monitored throughout and
body temperature maintained at 37 °C. MRI data were acquired using
a 7 T magnet (Magnex Scientiﬁc, Abingdon, UK), and a Varian Inova
spectrometer (Varian Inc, Palo Alto, USA). Sets of ﬁve coronal images
spanning the rat forebrain were acquired using a T2*-weighted FLASH
sequence (TE = 25 ms, TR = 500 ms, 40° ﬂip angle, ﬁeld of view
80 × 40 mm, matrix size 256 × 128, slice thickness 1.5 mm). Dynamic
updating of ﬁrst order shims was used for each slice to maximise fMRI
sensitivity (Blamire et al., 1996; Koch et al., 2006). Each set of ﬁve im-
ages was acquired over a 2 min time period. Anatomical images of the
same ﬁve coronal slices were acquired using a T2-weighted fast spin
echo sequence (TR = 3 s, TE = 45 ms, ﬁeld of view 30 × 30 mm,
matrix size 128 × 128). Imageswere acquired continuously throughout
the experimental protocol, which consisted of 15 min of baseline imag-
ing, followed by a bolus i.v. administration of either fenﬂuramine
(10 mg/kg i.v.) or vehicle over 1 min, and a further 85 min of image
acquisition. Thus, the ﬁrst 16 min (8 images) of data acquisition are
considered as baseline.
To determine the effect of systemic inﬂammation on the phMRI
response to fenﬂuramine, animals were injected intraperitoneally
with 0.5 mg/kg LPS (E. coli strain O111:B4; Sigma-Aldrich) in sterile
pyrogen-free saline to induce a systemic inﬂammatory response 6h
prior to fenﬂuramine administration (n = 6). Previous data show
that 0.5 mg/kg LPS is required to produce a robust febrile response
(Derijk et al., 1993). Control animals (n = 5) were injected with vehi-
cle, instead of LPS, 6 h prior to fenﬂuramine administration. Two further
control groups were included that received either LPS (n = 3) or saline
(n = 4) 6 h prior to phMRI during which vehicle was injected in place
of fenﬂuramine. The four groups are denoted as follows: LPS-Fen,
Veh-Fen, LPS-Veh and Veh-Veh.
In a further group of animals the effects of blocking the 5-HT2A recep-
tor on the phMRI response to fenﬂuramine were assessed. In these ani-
mals, a single dose of MDL100907 (0.5 mg/kg) was administered i.p.
via an indwelling cannula 15 min prior to either fenﬂuramine (n = 6)
or vehicle (n = 3) administration. The MRI acquisition was started
15 min prior to MDL100907 administration and a further 15 min of
baseline data were acquired following MDL100907 injection and prior
to fenﬂuramine/vehicle administration (total baseline data = 30 min).
In these groups image acquisition post-fenﬂuramine (or vehicle) was
shortened to 75 min owing to the longer baseline period. The data
were compared to animals injected with either fenﬂuramine (n = 5)
or vehicle alone (n = 4). These animals were not pre-injected with
vehicle given that the previous experiment had demonstrated no effect
of saline administration on the BOLD signal and, hence, the baseline
periodwas only 15 min in duration. Thus, the data from this experiment
are shown from 15 min prior to either fenﬂuramine or vehicle injection
for all groups. Again, the baseline period for analysiswas taken as 16 min
(8 images) in total to allow for the fenﬂuramine injection.
MRI data analysis
Analysis of the fMRI datasets was carried out using AFNI (http://
afni.nimh.nih.gov/afni/) and FEAT (http://www.fmrib.ox.ac.uk) soft-
ware packages (Jenkinson et al., 2012; Woolrich et al., 2009; Smith
et al., 2004). Datasets were corrected for any motion artefacts using
AFNI, and spatial smoothing performed in FEAT using a Gaussian
kernel of FWHM 1 mm. Statistical analysis was performed using a
general linear model within FEAT. The design matrix consisted of a
simple temporal model of the expected response, with 0 specifying
the baseline period and 1 or−1 specifying signal increases or decreases
during the post-drug period respectively. To generate activation maps,
we used the cluster-based thresholding approach described in Smith
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identify voxel clusters. A Z-statistic threshold of Z = 3.51 was used to
deﬁne contiguous clusters and the signiﬁcance level of each clusters
(fromGaussian random ﬁeld theory, Friston et al., 1995) was compared
with a cluster probability threshold of p b 0.05. A colour-coded
z-statistic map was then overlaid onto the corresponding phMRI gradi-
ent echo image. With reference to the anatomical images and a stereo-
taxic atlas (Paxinos et al., 1980), regions of interest (ROI) were
manually deﬁned on the functional datasets for anterior motor cortex,
nucleus accumbens and dorsal raphe nucleus. The average BOLD signal
intensity changes across all pixels over time within these ROIs was
determined, expressed as percentage change from baseline signal
intensity, and plotted as a function of time.
Brain microdialysis
Microdialysis probes were fabricated in-house using stainless steel
cannulae (23G, Cooper's Needle Works Ltd, United Kingdom) with a
semi-permeable membrane tip (3 mm effective tip length; 200 mm
I.D., 40,000 MW cut-off, 60 Å pore size, Hospal AN 69). Animals were
prepared as described above (n = 5 or 6 per group). Following trache-
otomy and vessel cannulations, animals were placed in a stereotaxic
frame (Stoetling Co., USA), the skull was exposed and a burr-hole drilled
above the right anterior motor cortex and the microdialysis probe
inserted stereotaxically (A/P +2.2 mm; M/L +2.8 mm; D/V −1 mm).
The microdialysis probe was perfused with artiﬁcial cerebral spinal
ﬂuid (aCSF; 140 mM NaCl, 3 mM KCl, 1.2 mM Na2HPO4, 0.27 mM
NaH2PO4, 1 mM MgCl2, 2.4 mM CaCl2 and 7.2 mM glucose) at a ﬂow
rate of 2 μl/min (CMA/100, CarnegieMedicine). The probewas perfused
for 1.5–2 h in situ prior to the start of dialysate collection. Samples were
subsequently collected over consecutive 20 min periods. At this point
animals were injectedwith fenﬂuramine (10 mg/kg i.v. in 0.1 ml saline)
as for the phMRI study, and a further six 20 min dialysate samples were
collected.
High pressure liquid chromatography
Dialysate samples were analysed using HPLC with electrochemical
detection and separated with an ACE column (C18, 3 μm, 125 ×
3 mm + ACE C18 guard, 10 × 3 mm run at 35°C). Samples were car-
ried by an eluent (12.5% methanol, 130 mM NaH2PO4, 0.85 mM Na2-
EDTA, 0.1 mM 1-octanesulphonic acid, pH 3.55) pumped with a ﬂow
rate of 0.6 ml/min (Waters 2695 HPLC Pump). Samples were detected
using a glassy carbon electrode held at+0.75 V (Dionex ED40). The di-
alysate content was determinedwith reference to daily-calibrated stan-
dard solutions in 0.06 M perchloric acid (5 pmol 5-HT and 5-HIAA).
Chromatograms were displayed and analysed using Waters Empower
2 software.
Laser Doppler ﬂowmetry
Six hours after either LPS or saline injection, animals (n = 5 per
group) were placed in a stereotaxic frame (Kopf Instruments), and a
region of skull overlying the right anterior motor cortex was thinned
to translucency using a dental drill. A laser Doppler probe (Perimed
Probe 403, Jarafalla, Sweden) was positioned above the visible corti-
cal surface. Carbon ﬁbre stimulating electrodes were inserted through
burr holes made in the skull overlying the contralateral MCx and
advanced over the cortical surface to a position overlying the anterior
motor cortex (Austin et al., 2003). Electrical stimuli were delivered to
the contralateral MCx and recordings of stimulus evoked cerebral
blood ﬂow changes were recorded using the laser Doppler probe.
For each laser Doppler experimental session, 2-s stimuli of 5, 10, 20,
30 and 40 Hz were presented in a randomised sequence (10 repeats
at each frequency) with a stimulus pulse width of 0.3 ms and an
inter-stimulus interval (ISI) of 25 s. All stimulus presentation wascontrolled through a 1401 plus (CED Ltd., UK) running custom-
written code.Autoradiography
Fresh frozen brain tissue was cut coronally at 12 μm. Adjacent
tissue sections were incubated with either 2 nM [3H]Ketanserin or
2 nM [3H] with 10 μM methylsergide. Sections were then placed in
a cassette with Kodak® BioMax® MR ﬁlm and exposed for approxi-
mately 6 weeks. Analysis was performed using MCID-Core software.(±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) induced
wet dog shake behaviour
Animals received a single dose of LPS as with previous experiments
and were allowed to recover for c. 6 h. On or around the 6 hour time
point animals received a single dose of DOI (1 mg/kg s.c.) and were
observed for 20 min, during which the number of wet dog shakes
(WDS) was counted. WDS behaviour constituted anything from a
head twitch to a full body shake and data are presented as total WDS
over 20 min.Statistics
In each case, the phMRI data were normalised to the ﬁrst 16 min
period of no-drug baseline acquisition (2 min temporal resolution;
baseline = 8 images). The phMRI data were then analysed in two dif-
ferent ways: in the ﬁrst instance, repeated measures analysis of vari-
ance (ANOVA) was used to compare the timecourses in each group
over the ﬁrst 46 min of data acquisition (16 min baseline + 30 min
after drug administration); in the second case, the mean BOLD signal
intensity was averaged over the ﬁrst 30 min post-fenﬂuramine (or
vehicle) administration (minutes 17–46 of acquisition) and assessed
using ANOVA to identify statistical differences between the experi-
mental groups. Where signiﬁcant differences were found in the LPS
study, post-hoc Dunnett's tests were used to identify differences
between each group and the Veh-Veh group. Where signiﬁcant differ-
ences were found in the MDL100907 study, post-hoc Tukey's tests
were used to identify pairwise differences between the groups. CBF
data were analysed by computing the area under the curve (AUC)
for each animal's trial-averaged response (at each stimulation
frequency). T-tests were performed at each stimulation frequency to
compare data between experimental groups. Microdialysis data
were analysed by t-test of the average area under curve across each
group. All other data was analysed by standard Student's t-tests.Results
Effect of fenﬂuramine on BOLD in rat brain regions
Physiological parameters were maintained within normal ranges
throughout each experiment: body temperature = 37 ± 0.5 °C;
pCO2 = 35–42 mmHg; pO2 ≥ 90 mmHg; pH = 7.4 ± 0.1;mean arte-
rial blood pressure = 120 ± 20 mm Hg. Fenﬂuramine (10 mg/kg i.v.)
evoked signiﬁcant and prolonged changes in BOLD signal intensity in
all three brain regions studied (Figs. 1 & 2A–C); anterior motor cortex
(MCx), nucleus accumbens (NAc) and dorsal raphe nucleus (DRN). In
particular, bilateral increases in BOLD signal intensity were evident
in the MCx, whilst decreases in BOLD signal intensity were found in
the NAc (Fig. 2B) and DRN (Fig. 2C). The maximum change observed
was+15.9 ± 2% of baseline in theMCx,−7.7 ± 5.3% in the NAc and
−9.9 ± 4.2% in the DRN.
A B C
Bregma 1.2mm Bregma -7.3mmBregma 3.2mm
MC MC
NAcNAc
DRN
Fig. 1. BOLD activation maps and ROIs. Representative z-score maps and Paxinos atlas images showing statistically signiﬁcant BOLD responses in (A) anterior motor cortex, (B) nucleus
accumbens and (C) dorsal raphe nucleus.
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Pre-treatment with LPS (0.5 mg/kg i.p.) 6 h prior to fenﬂuramine
administration signiﬁcantly reduced the BOLD response to fenﬂur-
amine. In all brain regions examined, ANOVA across the ﬁrst 46 min
of the time-course data (16 min baseline + 30 min post-fenﬂuramine
or vehicle; Figs. 2A–C) showed highly signiﬁcant (time p b 0.0001
F7,414 = 28.83, group:time p b 0.0001 F21,414 = 66.58) differences in
the BOLD time-course response to fenﬂuramine between the groups.
However, in the MCx and DRN, whilst post-hoc Dunnett's tests showed
that whilst the Veh-Fen time-course was signiﬁcantly different to the
Veh-Veh group (MCx, DRN p b 0.0001), neither the LPS-Fen nor the
LPS-Veh time-courses were signiﬁcantly different to the Veh-Veh
group. In the NAc both the Veh-Fen and the LPS-Fen groupswere signif-
icantly different to the Veh-Veh group, albeit to differing degrees;
p b 0.0001 and p b 0.05, respectively.
In the analysis of the averaged ﬁrst 30 min of data acquired
post-fenﬂuramine injection (see Materials & methods), highly signif-
icant (post-hoc Dunnett's test, p b 0.0001) differences were again
found between the Veh-Fen and Veh-Veh groups in all regions
(Figs. 2D–F). However, in this case small, but signiﬁcant, differences
were also found between LPS-Fen and Veh-Veh groups in all regions
(post-hoc Dunnett's test MCx p b 0.05, NAc p b 0.0001 and DRN
p b 0.01). In addition, The LPS-Veh group in the DRN showed a signif-
icant difference to the Veh-Veh group (post-hoc Dunnett's test
p b 0.05). These data suggest some residual effects of fenﬂuramine,
although from the time course analysis these effects appear minimal
with the BOLD responses to fenﬂuramine being largely abolished
(Figs. 2A–C).
Effect of systemic inﬂammation on fenﬂuramine-evoked release of 5-HT
To determine whether attenuation of the fenﬂuramine-evoked BOLD
response by LPSwas due to decreased 5-HT release, in vivomicrodialysis
of the MCx was carried out under the same conditions as the phMRI ex-
periments. The MCxwas chosen for these studies based primarily on the
fact that the largest BOLD changes in response to fenﬂuramine were
found in this area. However, Manganotti et al. (2001); Herwig et al.
(2002) have also shown that antidepressant treatment increases the ex-
citability of themotor cortex, possibly via a 5-HT-relatedmechanism. Ad-
ministration of fenﬂuramine (10 mg/kg i.v.) induced an increase in 5-HT
in cortical dialysates (Fig. 3). This increase in 5-HT was greatest 40 min
post-fenﬂuramine injection and 5-HT levels returned to baseline within
the following 60 min. In comparison, fenﬂuramine also evoked an in-
crease in 5-HT in animals pre-treated with LPS (0.5 mg/kg i.p., 6 h) and
themagnitude 5-HT response and duration of effect was not signiﬁcantly
different to animals receiving fenﬂuramine alone (Fig. 3). Fenﬂuraminehad no signiﬁcant effect on the levels of the principal 5-HT metabolite
5HIAA, and this was not different in animals treated with LPS.
Neurovascular coupling experiments
Laser-Doppler ﬂowmetry (LDF) monitoring of stimulus-evoked cere-
bral bloodﬂow(CBF) changeswasmade to verify that neurovascular cou-
pling and functional hyperaemic responses remained intact post-LPS
treatment (Figs. 4A–B). Six hours post-LPS administration (0.5 mg/kg
i.p.) area under the curve measurements of the CBF response showed
no signiﬁcant differences to those obtained from control animals
(Fig. 4C). Given that the BOLD signal measurements described above
were acquiredwith a temporal resolution of 120 s, an integratedmeasure
of total CBF response over time was used to characterise the stimulus
evoked CBF signal change rather than a readout of the transient response
maxima.
Effect of 5-HT2A receptor blockade on fenﬂuramine-induced BOLD
responses
Our previous studies demonstrated that fenﬂuramine-evoked
changes in activity-dependent gene expression involved 5-HT2A-
receptor activation (Hirani et al., 2003). For the time course analy-
sis (15 min baseline + 31 min post-fenﬂuramine or vehicle) pre-
treatment with the selective 5-HT2A receptor antagonist MDL100907
signiﬁcantly attenuated the BOLD response to fenﬂuramine compared
to untreated animals in the MCx and DRN (ANOVA group F3,14 =
22.31, time F7,460 = 38.79, group:time F21,460 = 38.79; post-hoc MCx
p b 0.0001, DRN; p b 0.0001; Figs. 5A, C). In these regions both groups
pre-treated with MDL (MDL-Fen and MDL-Veh) were signiﬁcantly
different to the animals given fenﬂuramine alone (post-hoc Tukey
p b 0.0001), but not to the control animals given vehicle alone. In
contrast, in the NAc MDL100907 did not appear to ameliorate the
response to fenﬂuramine, with both MDL-Fen and fenﬂuramine alone
groups showing signiﬁcant differences to the MDL-Veh and vehicle
alone groups (post-hoc Tukey p b 0.0001; Fig. 5B), but not to each other.
Similarly, in the MCx and DRN, analysis of the ﬁrst 30 min
post-fenﬂuramine (or vehicle) administration showed that the
response to fenﬂuramine was largely abolished with MDL100907
pre-treatment (Fig. 5D, ANOVA group p b 0.0001 F3,14 = 39.33;
post-hoc Tukey p b 0.001). No signiﬁcant differences were found
between the MDL-Fen, MDL-Veh and vehicle alone groups in the MCx
(Fig. 5D). However, although only minor differences in the BOLD
response time course were evident between the MDL-Fen, MDL-Veh
and vehicle only groups in the DRN (Fig. 5C), these differences reached
signiﬁcance in the analysis of the ﬁrst 30 min post-fenﬂuramine
(post-hoc Tukey p b 0.01; Fig. 5F) suggesting some residual effect of
0 5 10 15 20 25 30 35 40 45
60
80
100
120
Veh + Veh
Veh + Fen
LPS + Fen
LPS + Veh
Time (min)
0 5 10 15 20 25 30 35 40 45
60
80
100
120
Time (min)
0 5 10 15 20 25 30 35 40 45
60
80
100
120
Time (min)
A D
B E
C F
Veh + Veh Veh + Fen LPS + Fen LPS + Veh
60
80
100
120
***
*
Δ 
B
O
LD
 %
Veh + Veh Veh + Fen LPS + Fen LPS + Veh
60
80
100
120
***
***
Δ 
B
O
LD
 %
Veh + Veh Veh + Fen LPS + Fen LPS + Veh
60
80
100
120
***
** *
Δ 
B
O
LD
 %
Δ 
B
O
LD
 %
Δ 
B
O
LD
 %
Δ 
B
O
LD
 %
Fig. 2. (A–C) Time course plots showing the change in BOLD signal intensity in (A)motor cortex, (B) nucleus accumbens, and (C) dorsal raphe nucleus after administration of either LPS or
vehicle (0.9% saline i.p.) at t-6 h followed by either fenﬂuramine (10 mg/kg i.v.) or vehicle (0.9% saline i.v.) during imaging. Fenﬂuramine or vehicle was administered at t = 15 min
(arrow). Data represent mean ± SEM (n = 6). (D–F) Bar graphs showing mean ± SEM of the signal intensity over the ﬁrst 30 min after fenﬂuramine or vehicle administration.
*p b 0.05, **p b 0.01, ***p b 0.0001 (with respect to Veh-Veh).
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the BOLD response of the NAc to fenﬂuraminewas seen in theMDL-Fen
group compared to the fenﬂuramine alone group in the analysis of the
ﬁrst 30 min post-fenﬂuramine injection (Fig. 5E). At the same time,
the MDL-Fen group showed signiﬁcant differences to both the vehicle
only and MDL-Veh groups (post-hoc Tukey, p b 0.05 and 0.001, respec-
tively; Fig. 5E) conﬁrmingminimal effects of 5-HT2A antagonism on the
BOLD response to fenﬂuramine in the NAc.
To conﬁrm thatMDL100907 pre-treatment did not alter the baseline
BOLD signal the initial 15 min of baseline in the twoMDL100907 treated
groups was compared with the 15 min of baseline acquisition post-
MDL100907 administration. No signiﬁcant differences were found.
Systemic inﬂammation and 5-HT2A receptor expression
Changes in BOLD responses after systemic inﬂammation and in re-
sponse to 5-HT2A drugs may reﬂect post-synaptic changes in receptorexpression. Tissue was cryosectioned for autoradiographic analysis
using 3H-ketanserin, a 5-HT2A ligand. Expression of the 5-HT2A recep-
tor is largely restricted to the prefrontal areas of the brain, therefore
cryosections did not extend beyond the start of the hippocampus
(Lopez-Gimenez et al., 1997). 5-HT2A expression was measured in
saline (Fig. 6B) and LPS (Fig. 6C) brains and was found to be signiﬁ-
cantly increased in the cingulate MCx (Student’s t-test; p b 0.05)
and elevated, but not signiﬁcantly different from saline challenged
animals (p = 0.06), in the frontal MCx.
Effects of LPS on 5-HT2A-mediated behaviour
Whilst changes in 5-HT2A receptor expression and the adminis-
tration MDL100907 strongly indicate that LPS might alter 5-HT2A
signalling, it was important to demonstrate functional effects in a
5-HT2A-dependent behaviour. With this in mind, we used a direct
5-HT2Aagonist (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
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Fig. 3.Microdialysismeasurements of extracellular levels of 5-HT (A) and its mainmetab-
olite 5-HIAA (B), and the absolute concentrations of both (C), in theMCx following fenﬂur-
amine administration in control and LPS pre-treated rats. Fenﬂuramine (10 mg/kg i.v.)was
administered at t = 0 to animals that had received an i.p. injection of saline (solid line;
n = 6) or LPS (0.5 mg/kg i.p.; broken line; n = 5) 6 h prior to t = 0. Datawere calculated
as a percentage of baseline (mean ± SEM values are shown). Fig. 4. Effect of LPS treatment on neurovascular coupling and functional hyperaemia.
Time course of cerebral blood ﬂow (CBF) changes recorded in primary somatosensory
MCx in response to electrical stimulation of the contralateral somatosensory MCx in
(A) saline treated and (B) LPS treated animals (n = 3 per group). Stimuli were deliv-
ered using carbon ﬁbre electrodes positioned overlying the somatosensory MCx and
the stimulus evoked CBF changes were recorded using laser Doppler ﬂowmetry
probe positioned over the corresponding contralateral MCx. Stimuli consisted of a
2-s train of 0.3 ms 1.5 mA pulses at one of 5 frequencies (5, 10, 20, 30 and 40 Hz).
(C) CBF responses over the range of stimulation frequencies were quantiﬁed by deter-
mining area under the curve for the mean response to each condition for each animal.
182 Y. Couch et al. / NeuroImage 75 (2013) 177–186(DOI; 1 mg/kg subcutaneous) in the presence and absence of systemic
inﬂammation. Subcutaneous DOI administration in laboratory animals
elicits a very speciﬁc behavioural response; in rats it is known as wet
dog shake (WDS) behaviour. Both LPS and DOI had a signiﬁcant effect
on WDS shake behaviour, there was also a signiﬁcant interaction
(two-way ANOVA; DOI p b 0.001 F1,19 = 124.3; LPS p b 0.001
F1,19 = 38.17; LPS:DOI p b 0.001; F1,19 = 29.31). Post-hoc analysis
shows that when compared to vehicle, DOI induced signiﬁcantly more
WDS 6 h after a 0.1 ml i.p. injection of 0.9% saline (Bonferroni post-hoc;
p b 0.001). Administration of a single dose of 0.1 ml LPS in saline
(0.5 mg/kg i.p.) 6 h prior to DOI signiﬁcantly reduced the number of
observable WDS compared to the saline pre-treated control animals
(Bonferroni post-hoc p b 0.001 Fig. 7).
Discussion
The principal ﬁndings of the present study are that phMRI-
measured brain responses to the 5-HT releasing agent fenﬂuramine
were markedly reduced by prior administration of the systemic
inﬂammatory agent LPS, and that mechanistically these effects may
be mediated by changes in post-synaptic receptor expression. Our
data indicate not only that systemic inﬂammatory pathways affect
central 5-HT function, but that functional MRI outcomes, used in
both animals andman, can be altered by systemic immune system ac-
tivation. Our parallel microdialysis experiments showed that LPS did
not directly reduce fenﬂuramine-evoked 5-HT release, thereby rulingout a presynaptic 5-HT mechanism in this instance. Direct recordings
of stimulus evoked blood ﬂow responses further show that the effects
of LPS on the fMRI response to fenﬂuramine were not due to disrup-
tion of vascular reactivity or neurovascular coupling mechanisms.
Finally, results using 5-HT2A-targeting drugs indicate that some
aspects of sickness behaviour may be mediated by the 5-HT2A recep-
tor, whilst the fenﬂuramine evoked BOLD signal changes were atten-
uated by pre-treatment with the selective 5-HT2A receptor antagonist,
MDL100907. Taken together, these data suggest that contrary to
predictions from previous studies, the inhibitory effect of systemic
inﬂammation on central 5-HT function is mediated by a post- and
not presynaptic 5-HT mechanism, and that a downstream reduction
in 5-HT2A receptor signalling may play a key role in this inhibition.
Decreased BOLD responses to fenﬂuramine after systemic inﬂammation
We have recently reported that the 5-HT releasing agent fenﬂur-
amine elicits a pattern of BOLD signal changes across several brain
regions of the anaesthetised rat. This effect was attenuated by prior
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Fig. 5. (A–C) Time course plots showing the change in BOLD signal intensity in (A) motor cortex, (B) nucleus accumbens and (C) dorsal raphe nucleus following i.v. administration
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fenﬂuramine (MDL-fen) or vehicle (MDL-veh) injection. Data represent mean ± SEM (n = 5 per group). Fenﬂuramine or vehicle was administered i.v. at t = 15 min on the
time course plots (arrow; MDL100907 was administered at t = 0 min relative to these plots). (D–F) Bar graphs showing mean ± SEM of the signal intensity over the ﬁrst
30 min after fenﬂuramine or saline administration. *p b 0.05, ***p b 0.0001 (with respect to Veh-Veh); ++p b 0.01, +++p b 0.0001 (with respect to MDL-Veh); ###p b 0.0001
(with respect to MDL-Fen).
183Y. Couch et al. / NeuroImage 75 (2013) 177–1865-HT depletion, suggesting that the BOLD response to fenﬂuramine is
a surrogate marker of increased 5-HT release (Preece et al., 2009).
Consistent with these data, human studies report that the selective
5-HT re-uptake inhibitor citalopram, also evokes BOLD responses
(McKie et al., 2005). As shown previously, fenﬂuramine evoked
region-speciﬁc changes in BOLD signal in the current study.
Pre-treatment with LPS markedly attenuated the BOLD responses to
fenﬂuramine. This ﬁnding is in accord with human fMRI studies,
which show that changes in neuronal activity may be altered by
states of heightened immune compromise (Brydon et al., 2008).
Given the evidence that the fenﬂuramine-evoked BOLD changes are
5-HT-dependent (Preece et al., 2009), it seems likely that the effect
of LPS on the BOLD responses to fenﬂuramine is also mediated by
alteration of central 5-HT function.
Importantly, cortical in vivo microdialysis experiments demon-
strated that LPS administration did not alter either basal extracellular5-HT levels or its metabolite 5-HIAA, nor fenﬂuramine-evoked release
of cortical 5-HT. In previous studies we have demonstrated that fen-
ﬂuramine not only evoked cortical 5-HT release similar in magnitude
to that observed here, but that the 5-HT response to fenﬂuramine was
markedly attenuated in animals with depleted brain levels of 5-HT
(Series et al., 1994). Thus, in the MCx, at least, decreased 5-HT release
does not appear to underlie the LPS-induced suppression of BOLD
responses to fenﬂuramine.
Since systemic inﬂammation is well known to affect the vascula-
ture (Brydon et al., 2008), it was important to test whether LPS treat-
ment disrupted mechanisms linking changes in neuronal activity to
the hemodynamic responses. To this end, a model that we have pre-
viously used to study neurovascular coupling (Martin et al., 2006)
was used to verify that functional hyperaemic responses remained in-
tact in LPS treated animals. Although there was some variation in re-
sponses between LPS- and saline-treated animals, these experiments
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Fig. 6. 5-HT2A protein expression in the rat brain 6 h after an LPS challenge. Animals received a single i.p. dose of LPS 6 h prior to sacriﬁce, brains were sectioned coronally and
frontal regions were subjected to 3H-ketanserin autoradiography. The cingulate MCx and frontal MCx were deﬁned (A) and analysed using MCID Core Software. Representative
photomicrographs from ﬁlm autoradiograms from (B) saline and (C) LPS animals. Analysis shows data from (D) cingulate MCx and (E) frontal MCx. Data are mean ± SEM
(n = 3), *p b 0.05.
184 Y. Couch et al. / NeuroImage 75 (2013) 177–186demonstrated that it was still possible to elicit robust haemodynamic
responses to increased neuronal activity in the LPS treated animals.
Previous studies have shown that endotoxin-induced inﬂammation
signiﬁcantly alters CBF and disrupts autoregulation (Rosengarten et
al., 2008a, 2008b). Moreover it has been hypothesised that systemic
endotoxin causes a direct uncoupling of the cerebral microvascula-
ture from its neuronal input, but that this is not caused by
inﬂammation-induced oedema (Rosengarten et al., 2008a, 2008b).
In contrast, the current data show that in the MCx, at least,
neurovascular coupling mechanisms remain intact during the acute
phase of systemic inﬂammation. In the current study, a lower LPS
dose was used (0.5 mg/kg vs. 1–5 mg/kg) than that of Rosengarten
et al. and this may explain the discrepancy with earlier work.-
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represent mean ± SEM (n = 6/group), ***p b 0.001.BOLD responses to fenﬂuramine: role of 5-HT2A receptors
As shown previously (Preece et al., 2009), fenﬂuramine induced a
positive BOLD response in the MCx, but negative responses in both
the DRN and NAc. Pre-treatment with the selective 5-HT2A antagonist
MDL100907 effectively blocked the BOLD response to fenﬂuramine in
both MCx and DRN, whilst attenuation of the BOLD response in the
NAc was only partial. These ﬁndings suggest a strong involvement
of the 5-HT2A receptor in the BOLD response to increased 5-HT in
the MCx and DRN, but the involvement of additional receptor(s) for
5-HT or other neurotransmitters in the NAc. Candidate excitatory
5-HT receptor subtypes in NAc that would not be blocked by
MDL100907 include 5-HT2C, 5-HT4 and 5-HT6 receptors. Previous
studies have detected non-5-HT-mediated changes in Fos response
to fenﬂuramine in the caudate nucleus (Javed et al., 1998), and
other studies report that fenﬂuramine releases catecholamines at
higher doses (Balcioglu and Wurtman, 1998). Thus, although fenﬂur-
amine may primarily release 5-HT, a minor contribution from other
transmitters is possible in the NAc.
The BOLD increase in MCx induced by fenﬂuramine most likely
reﬂects activation of postsynaptic 5-HT2A receptors, which are excitato-
ry and abundant in this region. In comparison, there is a low abundance
of 5-HT2A receptors in the DRN suggesting that a component of this ef-
fect may bemediated by 5-HT2A receptors located outside the DRN. We
have previously demonstrated evidence for a feedback loop from the
anterior MCx to the DRN involving cortical glutamatergic neurones
that synapse onto local GABAergic neurons in the DRN (Hajos et al.,
1998; Varga et al., 2001), which is likely mediated by 5-HT2A receptors
in MCx (Boothman et al., 2003; Sharp et al., 2007). This cortical-raphe
control system can be altered under conditions of stress has been
reviewed by Stein et al. (2007). Thus, the fenﬂuramine-evoked decrease
in BOLD signal observed in the DRN might, in part, be triggered by cor-
tical 5-HT2A receptors, which excite cortico-raphe projections leading to
a reduction in neuronal activity in the DRN through activated local
GABAergic neurons. The fenﬂuramine-evoked BOLD decrease observed
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GABA neurons (Ward and Dorsa, 1996), although there is likely a
contribution from additional mechanisms as discussed above.
It should be noted that the BOLD responses measured herein may
not be entirely neurally mediated. There is much evidence to suggest
that certain 5-HT receptors, including 5-HT2A receptors, are expressed
on the microvasculature of the CNS (Brydon et al., 2008). Whilst the
cellular location and function of these receptors remains unclear,
there is evidence to suggest that 5-HT2A receptors mediate both ves-
sel contraction (Martin et al., 2006) and dilation (Rosengarten et al.,
2008a, 2008b) in the brain. Although there is a report suggesting
that 5-HT2A receptor blockade inhibits CBF in a model of cortical
spreading depression (Gold et al., 1998), it was noted that factors
such as vascular size and presence of the blood brain barrier may
affect whether 5-HT dilates or contracts arterioles. Nevertheless,
some of the observed effects of 5-HT2A blockade may reﬂect modula-
tion of these directly vascular actions of 5-HT on 5-HT2A receptors.
5-HT2A receptors in sickness behaviour and depression
There is much evidence that links 5-HT2A receptors to depression
and a decrease in 5-HT2A receptor function would seem in keeping
with the general view that decreased 5-HT function is an important de-
pression vulnerability factor. However, data regarding the role of 5-HT2A
receptors in depression are currently contradictory. For example, some
post-mortem studies of depressed suicide victims report decreased
5-HT2A receptor binding23, whilst others show an increase21-22. Positron
emission tomography studies have also investigated 5-HT2A receptor ex-
pression in depressed patients, but ﬁndings to date have been inconsis-
tent (Bhagwagar et al., 2004; Meyer et al., 1999). On the other hand,
5-HT2A agonists are being pursued as a target to relieve depression
and to trigger molecular effects linked to antidepressant action. Oddly,
5-HT2A antagonists also have antidepressant augmenting properties
(Celada et al., 2004). Thus, the relationship between systemic inﬂamma-
tion and changes in 5-HT function observed here cannot yet be readily
linked to depression vulnerability. In our study, expression of the
5-HT2A receptor in the prefrontal MCx of animals increased in response
to systemic inﬂammation. Other studies using different inﬂammatory
agents such as carrageenan have also shown increased 5-HT2A receptor
expression (Zhang et al., 2001). Non-inﬂammatory stressors also cause
an increase in 5-HT2A receptor expression in the MCx and in the hippo-
campus (Watanabe et al., 1993). The precise mechanism of activation of
increased 5-HT2A receptor expression is unclear, but it may involve di-
rect cytokine induced gene expression changes, but it may also reﬂect
indirect mechanisms. In culture, cytokines have been shown to reduce
signal transduction through the 5-HT2A receptor, via mechanisms
involving subcellular kinases (Kugaya et al., 1995). Cortisol and cortico-
trophin releasing hormone are induced by circulating cytokines, and it is
also possible that the 5-HT2A expression changes may also be a conse-
quence of HPA axis activation (Leonard, 2005). HPA axis activation
appears to be a homeostatic response to elevated cytokine expression
and it is often difﬁcult to work out whether it is the afferent or efferent
arm of the CNS response that is responsible for the molecular changes
associated with injury or disease. Our BOLD data and the expression
data provide good evidence to infer a direct effect of LPS on 5-HT2A
receptor signal transduction, but the demonstration of a direct action
of LPS on 5-HT2A signalling was important. The DOI data reported here
demonstrate that LPS administration does result in a signiﬁcant loss of
5-HT2A-mediated behaviour despite increased receptor expression. It is
not unusual for mRNA levels and protein levels to increase, as the
functionality is lost in many biological scenarios. For example, chronic
ﬂuoxetine treatment increases 5-HT2A receptor binding potential in
the frontal cortex, whilst fenﬂuramine-induced prolactin release was
blunted, suggesting desensitisation of the 5-HT2A receptor (Sawyer et
al., 2012). Interestingly, in their study, measures of pre-synaptic seroto-
nergic function were unaffected. These results extend the work ofKouhata et al. (2001) who showed that at 1 and 3 h after LPS,
DOI-induced WDS were decreased in a cyclooxygenase-dependent
manner. The 0.5 mg/kg dose of LPS used in this experiment, and in
those of Kouhata, did inhibit spontaneous locomotor activity and might
be viewed as a confound in the WDS paradigm. However, data from
other studies, using pro-inﬂammogens at concentrations which do not
inhibit locomotor activity, still show a reduction in WDS behaviour
(Kugaya et al., 1996) suggesting that the behaviour is 5-HT2A speciﬁc.
In summary, the current data suggest that the mechanisms underly-
ing the effects of systemic inﬂammation on the BOLD response to fenﬂur-
amine are not pre-synaptic in origin, speciﬁcally through compromised
5-HT release, and that they do not reﬂect disruption of neurovascular
coupling capacity. However, the pattern of LPS-induced effects is
strikingly similar to those observed with a speciﬁc 5-HT2A receptor an-
tagonist. These ﬁndings, in combination with inﬂammation-induced
changes in 5-HT2A expression and 5-HT2A-mediated behaviours, suggest
that the effects of systemic inﬂammation on central 5-HT function reﬂect,
at least in part, modulation of 5-HT2A signalling pathways.
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